Clinical Trial Update: Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Savolitinib plus Durvalumab versus Sunitinib and Durvalumab monotherapy in MET-driven papillary renal cell carcinoma; the study is curre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Papillary Renal Cell Carcinoma

Drugs mentioned

• Durvalumab (durvalumab)
• Savolitinib (savolitinib)
• Sunitinib (sunitinib)

Snippet

Sponsor: AstraZeneca | Conditions: Papillary Renal Cell Carcinoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING